Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-003478.pdf
0001179110-20-003478.rtf
0001179110-20-003478.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-003477.pdf
0001179110-20-003477.rtf
0001179110-20-003477.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002957.pdf
0001179110-20-002957.rtf
0001179110-20-002957.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002955.pdf
0001179110-20-002955.rtf
0001179110-20-002955.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002956.pdf
0001179110-20-002956.rtf
0001179110-20-002956.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002958.pdf
0001179110-20-002958.rtf
0001179110-20-002958.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002959.pdf
0001179110-20-002959.rtf
0001179110-20-002959.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002961.pdf
0001179110-20-002961.rtf
0001179110-20-002961.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002960.pdf
0001179110-20-002960.rtf
0001179110-20-002960.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-002963.pdf
0001179110-20-002963.rtf
0001179110-20-002963.xls